Recent pre-clinical studies in mice show that glucagon blockers can improve heart function in HFpEF, a type of heart failure.

For patients with HFPEF and other underlying comorbidities ... taking open-label ACE inhibitors after cessation of blinded therapy—40% of patients taking perindopril and 36% of placebo subjects ...

Mavacamten, a drug initially developed to treat hypertrophic cardiomyopathy, has shown signs of reducing heart stress in ...

Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.

Which mineralocorticoid receptor antagonists (MRAs; ie, steroidal, nonsteroidal) are currently indicated or used for treating heart failure with midrange ejection fraction (HFmrEF) and HF failure ...

Novel therapies for HFmrEF and HFpEF aim to improve symptom management and patient outcomes, addressing current treatment limitations. Emerging treatments could reduce hospitalization rates and ...

FRIDAY, Sept. 20, 2024 (HealthDay News) -- For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ventricular (LV) diastolic function ...

For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ventricular (LV) diastolic function, according to a study published online Sept.

Mavacamten had been FDA approved on the basis of the EXPLORER-HCM trial's finding that the drug resulted in better functional ...

Global Commercial Launch Preparations Underway for First Potential Approval Towards Building Specialty Cardiovascular Franchise Company Recently Launched Unbranded Disease Awareness Campaign “HCM ...